Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duobrii in mild plaque psoriasis
NCT05203315Phase 3Completed
- Sponsor
- Austin Institute for Clinical Research
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of halobetasol propionate + tazarotene in plaque psoriasis, sponsored by Austin Institute for Clinical Research. Started Jan 2022; status: completed.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05203315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203315.